Efruxifermin (AKR-001) is an investigational drug developed by Akero Therapeutics, acting as a fibroblast growth factor 21 (FGF21) analog developed to treat metabolic dysfunction …

Jul 8, 2021 · Efruxifermin is a fusion protein of human IgG 1 Fc domain linked to a modified human FGF21 (Fc-FGF21) with balanced in vitro agonist potency at FGFR1c, FGFR2c and …

Our multi-modal investigational drug, efruxifermin (EFX), is designed to treat MASH holistically. EFX has been engineered to mimic the biological activity of fibroblast growth factor 21 …

Oct 3, 2023 · Efruxifermin is a bivalent Fc-FGF21 analogue that replicates FGF21 agonism of fibroblast growth factor receptor 1c, 2c, or 3c. The aim of this phase 2b study was to assess its …

Areas covered: Efruxifermin (EFX, also AKR-001 or AMG876) is an engineered Fc-FGF21 fusion protein with an optimized pharmacokinetic and pharmacodynamic profile, which is currently …

Oct 3, 2023 · Efruxifermin is a bivalent Fc–FGF21 analogue that replicates FGF21 agonism of fibroblast growth factor receptor 1c, 2c, or 3c. The aim of this phase 2b study was to assess its …

In this challenging well-compensated cirrhotic population, a clinically meaningful but not yet significant clinical benefit was seen in as early as 36 weeks. The totality of the data to include …

Efruxifermin is an Fc‐FGF21 fusion protein with prolonged half‐life and enhanced receptor affinity compared with native human FGF21. Efruxifermin is in clinical trials for the treatment of …

Mar 4, 2024 · Efruxifermin improves liver histology and markers of liver injury and fibrosis in patients with MASH. In this 12-week phase 2b study, efruxifermin, added to a GLP-1RA in …

Preclinical and clinical data suggest that fibroblast growth factor 21 (FGF21) is anti-fibrotic, improves metabolic status and has potential to treat non-alcoholic steatohepatitis (NASH). We …